Kodiak Sciences Inc (KOD)

Kodiak Sciences Inc. (KOD) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to treat chronic, high-prevalence retinal diseases. The company's lead product candidate is KSI-301, an anti-VEGF therapy designed to maintain efficacy with less frequent injections than current standard-of-care treatments. KOD is also developing KSI-501, a bispecific anti-IL-6/VEGF bioconjugate designed to address inflammation and angiogenesis associated with retinal vascular diseases. The company is headquartered in Palo Alto, California.